Evaluating Men with Obesity: Understanding Low Testosterone Levels

Overview

Men with obesity often exhibit mild to moderate reductions in serum testosterone accompanied by normal LH and FSH levels, a condition termed pseudo-hypogonadism. This state is reversible with weight loss and management of obesity-related comorbidities, and does not warrant testosterone replacement therapy.

Background

Obesity is associated with numerous chronic diseases and is strongly linked to reductions in circulating testosterone levels, primarily due to decreased sex hormone-binding globulin (SHBG). Despite common misconceptions, low testosterone in obese men does not indicate pathological hypogonadism caused by structural or genetic disorders of the hypothalamic-pituitary-testicular axis. Misinterpretation of low testosterone levels in obesity has contributed to widespread off-label testosterone use without proven benefit or safety in this population.

Data Highlights

Key Findings

• Obesity-related reductions in serum testosterone are primarily due to decreased SHBG rather than true hypogonadism.
• Serum LH and FSH levels remain normal in obese men with low testosterone, indicating preserved hypothalamic-pituitary-testicular axis function.
• Pseudo-hypogonadism of obesity is a reversible condition with weight loss and management of comorbidities such as type 2 diabetes and obstructive sleep apnea.
• Testosterone replacement therapy is not indicated in obesity-related low testosterone and may cause adverse effects including infertility and elevated hematocrit.
• Lifestyle interventions and optimizing treatment of obesity-related illnesses are more effective than testosterone therapy in improving symptoms and testosterone levels.

Clinical Implications

Clinicians should recognize that low testosterone in men with obesity often reflects a reversible, nongonadal illness syndrome rather than true hypogonadism. Prioritizing weight loss and management of comorbid conditions is essential before considering testosterone therapy. Avoiding unwarranted testosterone treatment can prevent potential adverse effects and dependence.

Conclusion

Obesity-associated low testosterone represents a pseudo-hypogonadism state that is reversible with appropriate lifestyle and medical interventions. Testosterone replacement therapy is generally not justified in this context and should be reserved for men with confirmed pathological hypogonadism.

References

1. Grossmann M, et al. 2023 -- Evaluating Men with Obesity: Understanding Low Testosterone Levels